Ezetimibe: cholesterol lowering and beyond

References

• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Circulation110(2), 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Bays H, McKenney J, Davidson M. Torcetrapib/atorvastatin combination therapy. Expert Rev. Cardiovasc. Ther.3(5), 789–820 (2005).
   PubMedGoogle Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet360(9326), 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Smith B, Maheshwari, N, Schrott H. Pleiotropic effects of statins beyond cholesterol reduction? J. Am. Coll. Cardiol.46(10), 1855–1862 (2005).
   PubMed Web of Science ®Google Scholar
• Bays H. Ezetimibe. Expert Opin. Investig. Drugs11(11), 1587–1604 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Davidson MH. Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction. Expert Rev. Cardiovasc. Ther.4(4), 461–476 (2006).
   PubMedGoogle Scholar
• Burnett JR, Huff MW. Cholesterol absorption inhibitors as a therapeutic option for hypercholesterolaemia. Expert Opin. Investig. Drugs15(11), 1337–1351 (2006).
   PubMed Web of Science ®Google Scholar
• Santosa S, Varady KA, AbuMweis S, Jones PJ. Physiological and therapeutic factors affecting cholesterol metabolism: does a reciprocal relationship between cholesterol absorption and synthesis really exist? Life Sci.80(6), 505–514 (2007).
   PubMed Web of Science ®Google Scholar
• Turley SD, Dietschy JM. Sterol absorption by the small intestine. Curr. Opin. Lipidol.14(3), 233–240 (2003).
   PubMed Web of Science ®Google Scholar
• Bays H, Dujovne C. Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin. Pharmacother.4(5), 779–790 (2003).
   PubMed Web of Science ®Google Scholar
• Mayes PA. Cholesterol synthesis, transport and excretion. In: Harper’s Biochemistry (25th Edition). Murray RK, Granner DK, Mayes PA, Rodwell VW (Eds). Appleton & Lange, CT, USA, 285–305 (2000).
   Google Scholar
• Dietschy JM, Turley SD, Spady DK. Role of liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans. J. Lipid. Res.34(10), 1637–1659 (1993).
   PubMed Web of Science ®Google Scholar
• Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ. Res.96(12), 1221–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Ikonen E. Mechanisms for cellular cholesterol transport: defects and human disease. Physiol. Rev.86(4), 1237–1261 (2006).
   PubMed Web of Science ®Google Scholar
• Gylling H. Cholesterol metabolism and its implications for therapeutic interventions in patients with hypercholesterolaemia. Int. J. Clin. Pract.58(9), 859–866 (2004).
   PubMed Web of Science ®Google Scholar
• Kruit JK, Groen AK, van Berkel TJ, Kuipers F. Emerging roles of the intestine in control of cholesterol metabolism. World J. Gastroenterol.12(40), 6429–6439 (2006).
   PubMed Web of Science ®Google Scholar
• Lee MH, Lu K, Hazard S et al. Identification of a gene, ABCG5, important in the regulation of dietary cholesterol absorption. Nat. Genet.27(1), 79–83 (2001).
   PubMed Web of Science ®Google Scholar
• Wang, Q-H. Regulation of intestinal cholesterol absorption. Annu. Rev. Physiol.69, 221–48 (2007).
   PubMed Web of Science ®Google Scholar
• Berge KE, Tian H, Graf GA et al. Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science290(5497), 1771–1775 (2000).
   PubMed Web of Science ®Google Scholar
• Stanek EJ, Sarawate C, Willey VJ, Charland SL, Cziraky MJ. Risk of cardiovascular events in patients at optimal values for combined lipid parameters. Curr. Med. Res. Opin.23(3), 553–563 (2007).
   PubMed Web of Science ®Google Scholar
• Salen G, von Bergmann K, Lutjohann D et al. Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia. Circulation109(8), 966–971 (2004).
   PubMed Web of Science ®Google Scholar
• Yu LQ, Li-Hawkins J, Hammer RE et al. Overexpression of ABCG5 and ABCG8 promotes biliary cholesterol secretion and reduces fractional absorption of dietary cholesterol. J. Clin. Invest.110(5), 671–680 (2002).
   PubMed Web of Science ®Google Scholar
• Kruit JK, Plosch T, Havinga R et al. Increased fecal neutral sterol loss upon liver X receptor activation is independent of biliary sterol secretion in mice. Gastroenterology128(1), 147–156 (2005).
   PubMed Web of Science ®Google Scholar
• Brunham LR, Kruit JK, Iqbal J et al. Intestinal ABCA1 directly contributes to HDL biogenesis in vivo. J. Clin. Invest.116(4), 1052–1062 (2006).
   PubMed Web of Science ®Google Scholar
• Wu AL, Windmueller HG. Relative contributions by liver and intestine to individual plasma apolipoproteins in the rat. J. Biol. Chem.254(45), 7316–7322 (1979).
   PubMed Web of Science ®Google Scholar
• Davis HR, Zhu LJ, Hoos LM et al. Niemann–Pick C1 like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis. J. Biol. Chem.279(32), 33586–33592 (2004).
   PubMed Web of Science ®Google Scholar
• Garcia-Calvo M, Lisnock JM, Bull HG et al. The target of ezetimibe is Niemann-Pick Cl-Like 1 (NPC1L1). Proc. Natl. Acad. Sci. USA102(23), 8132–8137 (2005).
   PubMed Web of Science ®Google Scholar
• Lammert F, Wang DQ. New insights into the genetic regulation of intestinal cholesterol absorption. Gastroenterology129(2), 718–734 (2005).
   PubMed Web of Science ®Google Scholar
• Catapano AL. The pharmacologic elegance of inhibiting cholesterol absorption and synthesis while providing a homeostatic balance. Fundam. Clin. Pharmacol.21 (2), 21–26, (2007).
   PubMedGoogle Scholar
• Ternel RE, Tang W, Ma Y et al. Hepatic Niemann–Pick C1-like 1 regulate biliary concentration and is a target of ezetimibe. J. Clin Invest.117 (7), 1968–1978 (2007).
   PubMed Web of Science ®Google Scholar
• van Heek M, Compton DS, Davis HR. The cholesterol absorption inhibitor, ezetimibe, decreases diet-induced hypercholesterolemia in monkeys. Eur. J. Pharmacol.415(1), 79–84 (2001).
   PubMed Web of Science ®Google Scholar
• Bays H, Stein EA. Pharmacotherapy for dyslipidaemia – current therapies and future agents. Expert Opin. Pharmacother.4(11), 1901–1938 (2003).
   PubMed Web of Science ®Google Scholar
• Davis HR, Compton DS, Hoos LM, Tetzloff GG. Ezetimibe reduces plasma cholesterol and inhibits the development of atherosclerosis in apo E knockout mice with and without LDL receptors. Circulation102(18), 186 (2000).
   Google Scholar
• Repa JJ, Turley SD, Quan G, Dietschy JM. Delineation of molecular changes in intrahepatic cholesterol metabolism resulting from diminished cholesterol absorption. J. Lipid. Res.46(4), 779–789 (2005).
   PubMed Web of Science ®Google Scholar
• Tremblay AJ, Lamarche B, Cohn JS, Hogue JC, Couture P. Effect of ezetimibe on the in vivo kinetics of apoB-48 and apoB-100 in men with primary hypercholesterolemia. Arterioscler. Thromb. Vasc. Biol.26(5), 1101–1106 (2006).
   PubMed Web of Science ®Google Scholar
• Hachem SB, Mooradian AD. Familial dyslipidaemias: an overview of genetics, pathophysiology and management. Drugs66(15), 1949–1969 (2006).
   PubMed Web of Science ®Google Scholar
• Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation105(21), 2469–2475 (2002).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearny PM et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366(9493), 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Lamon-Fava S, Diffenderfer MR, Barrett PH et al. Effects of different doses of atorvastatin on human apolipoprotein B-100, B-48, and A-I metabolism. J. Lipid Res.48(8), 1746–1753 (2007).
   PubMed Web of Science ®Google Scholar
• Holdgate GA, Ward WHJ, McTaggart F. Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem. Soc. Trans.31(Pt 3), 528–531 (2003).
   PubMed Web of Science ®Google Scholar
• Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr. Drug Targets Cardiovasc. Haematol. Disord.5(6), 455–462 (2005).
   PubMedGoogle Scholar
• Miettinen TA, Gylling H. Ineffective decrease of serum cholesterol by simvastatin in a subgroup of hypercholesterolemic coronary patients. Atherosclerosis164(1), 147–152 (2002).
   PubMed Web of Science ®Google Scholar
• Miettinen TA, Gylling H. Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment. Eur. J. Clin. Invest.33(11), 976–982 (2003).
   PubMed Web of Science ®Google Scholar
• Altmann SW, Davis HR, Zhu LJ et al. Niemann-Pick C1 like 1 protein is critical for intestinal cholesterol absorption. Science303(5661), 1201–1204 (2004).
   PubMed Web of Science ®Google Scholar
• Vasudevan AR, Jones PH. Effective use of combination lipid therapy. Curr. Atheroscler. Rep.8(1), 76–84 (2006).
   PubMedGoogle Scholar
• Telford DE, Sutherland BG, Edwards JY, Andrews JD, Barrett PH, Huff MW. The molecular mechanisms underlying the reduction of LDL apoB-100 by ezetimibe plus simvastatin. J. Lipid. Res.48(3), 699–708 (2007).
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lutjohann D, Kodal A et al. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation106(15), 1943–1948 (2002).
   PubMed Web of Science ®Google Scholar
• Bays HE, Moore PB, Drehobl MA et al. Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two Phase II studies. Clin. Ther.23(8), 1209–1230 (2001).
   PubMed Web of Science ®Google Scholar
• Dujovne CA, Ettinger MP, McNeer JF et al. Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia. Am. J. Cardiol.90(10), 1092–1097 (2002).
   PubMed Web of Science ®Google Scholar
• Knopp RH, Gitter H, Truitt T et al. Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia. Eur. Heart J.24(8), 729–741 (2003).
   PubMed Web of Science ®Google Scholar
• Stein E. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor. Eur. Heart J.3(Suppl. E), E11–E16 (2001).
   Web of Science ®Google Scholar
• Mandema JW, Hermann D, Wang W et al. Model-based development of gemcabene, a new lipid-altering agent. AAPS J.7(3), E513–E522 (2005).
   PubMed Web of Science ®Google Scholar
• Zetia. Product insert. 2001.
   Google Scholar
• Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am. J. Cardiol.90(10), 1084–1091 (2002).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Denke MA, McBride PE, Battisti WP, Brady WE, Palmisano J. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial. Mayo Clin. Proc.80(5), 587–595 (2005).
   PubMed Web of Science ®Google Scholar
• Masana L, Mata P, Gagne C et al. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study. Clin. Ther.27(2), 174–184 (2005).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Ballantyne CM, Kerzner B et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia. Int. J. Clin. Pract.58(8), 746–755 (2004).
   PubMed Web of Science ®Google Scholar
• Davidson MH, McGarry T, Bettis R et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J. Am. Coll. Cardiol.40(12), 2125–2134 (2002).
   PubMed Web of Science ®Google Scholar
• Goldberg AC, Sapre A, Liu J, Capece R, Mitchel YB. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin. Proc.79(5), 620–629 (2004).
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol.93(12), 1481–1486 (2004).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Blazing MA, King TR, Brady WE, Palmisano J. Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia. Am. J. Cardiol.93(12), 1487–1494 (2004).
   PubMed Web of Science ®Google Scholar
• Sager PT, Melani L, Lipka L et al.for the Ezetimibe Study Group. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am. J. Cardiol.92(12), 1414–1418 (2003).
   PubMed Web of Science ®Google Scholar
• Sager PT, Capece R, Lipka L et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis179(2), 361–367 (2005).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation107(19), 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Bays HE, Ose L, Fraser N et al. A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia. Clin. Ther.26(11), 1758–1773 (2004).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Abate N, Yuan Z, King TR, Palmisano J. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study. Am. Heart J.149(3), 464–473 (2005).
   PubMed Web of Science ®Google Scholar
• Catapano AL, Davidson MH, Ballantyne CM et al. Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients. Curr. Med. Res. Opin.22(10), 2041–2053 (2006).
   PubMed Web of Science ®Google Scholar
• Simons L, Tonkon M, Masana L et al. Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome. Curr. Med. Res. Opin.20(9), 1437–1445 (2004).
   PubMed Web of Science ®Google Scholar
• Denke M, Pearson T, McBride P, Gazzara RA, Brady WE, Tershakovec AM. Ezetimibe added to ongoing statin therapy improves LDL-C goal attainment and lipid profile in patients with diabetes or metabolic syndrome. Diab. Vasc. Dis. Res.3(2), 93–102 (2006).
   PubMedGoogle Scholar
• Goldberg RB, Guyton JR, Mazzone T et al. Ezetimibe/Simvastatin vs atorvastatin in patients with Type 2 diabetes mellitus and hypercholesterolemia: The VYTAL study. Mayo Clin. Proc.81(12), 1579–1588 (2006).
   PubMed Web of Science ®Google Scholar
• Smith SC, Jr, Allen J, Blair SN et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation113(19), 2363–2372 (2006).
   PubMed Web of Science ®Google Scholar
• Grundy SM. Low-density lipoprotein, non-high-density lipoprotein, and apolipoprotein B as targets of lipid-lowering therapy. Circulation106(20), 2526–2529 (2002).
   PubMed Web of Science ®Google Scholar
• Chapman MJ and Caslake M. Non-high-density lipoprotein cholesterol as a risk factor: addressing risk associated with apolipoprotein B-containing lipoproteins. Eur. Heart J. Supplements6, A43-A48 (2004).
   Google Scholar
• National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation106(25), 3143–3421 (2002).
   PubMed Web of Science ®Google Scholar
• Robinson JG, Davidson MH, Shah A et al. Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 65–74 and 75 years and older Aging Health3(6) 691–705 (2007).
   Google Scholar
• American Diabetes Association. Standards of medical care in diabetes – 2006. Diabetes Care29(Suppl. 1), S4–S42 (2006).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and Management of the Metabolic Syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Executive Summary. Circulation112(17), e285–e290 (2005).
   Google Scholar
• Guerin M, Lassel TS, Le Goff W, Farnier M, Chapman MJ. Action of atorvastatin in combined hyperlipidemia – preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler. Thromb. Vasc. Bio.20(1), 189–197 (2000).
   PubMed Web of Science ®Google Scholar
• Schaefer EJ, Asztalos BF. The effects of statins on high-density lipoproteins. Curr. Atheroscler. Rep.8(1), 41–49 (2006).
   PubMedGoogle Scholar
• Timmins JM, Lee JY, Boudyguina E et al. Targeted inactivation of hepatic Abca1 causes profound hypoalphalipoproteinemia and kidney hypercatabolism of apoA-I. J. Clin. Invest.115(5), 1333–1342 (2005).
   PubMed Web of Science ®Google Scholar
• Chung BH, Liang P, Doran S, Cho BH, Franklin F. Postprandial chylomicrons: potent vehicles for transporting cholesterol from endogenous LDL+HDL and cell membranes to the liver via LCAT and CETP. J. Lipid Res.45(7), 1242–1255 (2004).
   PubMed Web of Science ®Google Scholar
• Taggart W, Lutjohann D, Musliner T, Sudhop T, Shah A, von Bergmann K. Inhibition of intestinal cholesterol absorption and endogenous cholesterol production by ezetimibe/simvastatin in man. J. Clin. Lipid.1(5), 437 (2007).
   Google Scholar
• Briand F, Millar J, Billheimer J, Rothblat G, Rader D. Inhibition of cholesterol absorption with ezetimibe promotes macrophage to feces reverse cholesterol transport in mice. Circulation116, II159– II160 (2007).
   Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJP et al. for the Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: a randomized controlled trial. JAMA294, 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• Waters DD, Guyton JR, Herrington DM, McGowan MP, Wenger NK, Shear C; TNT Steering Committee Members and Investigators Treating to New Targets (TNT) Study. Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit? Am. J. Cardiol.93, 154–158 (2004).
   PubMed Web of Science ®Google Scholar
• Barter PJ, Ballantyne CM, Carmena R et al. Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J. Intern. Med.259(3), 247–258 (2006).
   PubMed Web of Science ®Google Scholar
• Sniderman AD. Apolipoprotein B versus non-high-density lipoprotein cholesterol: and the winner is… Circulation112(22), 3366–3367 (2005).
   PubMed Web of Science ®Google Scholar
• Stein EA, Sniderman A, Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am. J. Cardiol.96(9A), 36K–43K (2005).
   Web of Science ®Google Scholar
• Pischon T, Girman CJ, Sacks FM, Rifai N, Stampfer MJ, Rimm EB. Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation112(22), 3375–3383 (2005).
   PubMed Web of Science ®Google Scholar
• Genest J, Frohlich J, Fodor G, McPherson R. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. CMAJ169(9), 921–924 (2003).
   PubMed Web of Science ®Google Scholar
• Denke MA. Weighing in before the fight: low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol versus apolipoprotein B as the best predictor for coronary heart disease and the best measure of therapy. Circulation112(22), 3368–3370 (2005).
   PubMed Web of Science ®Google Scholar
• Basso F, Freeman LA, Ko C et al. Hepatic ABCG5/G8 overexpression reduces apoB-lipoproteins and atherosclerosis when cholesterol absorption is inhibited. J. Lipid Res.48(1), 114–126 (2007).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med.347(20), 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Pearson TA, Mensah GA, Alexander RW et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation107(3), 499–511 (2003).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med.352(1), 29–38 (2005).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med.352(1), 20–28 (2005).
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne CM, Sisk C, Shah A, Veltri ER, Maccubbin D. Comparison of effects of ezetimibe/simvastatin versus simvastatin versus atorvastatin in reducing C-reactive protein and low-density lipoprotein cholesterol levels. Am. J. Cardiol.99(12), 1706–1713 (2007).
   PubMed Web of Science ®Google Scholar
• Pearson T, Ballantyne CM, Veltri ER et al. CRP and D LDL-C response to ezetimibe: monotherapy and add-on to baseline statin. Triennial international symposium on drugs affecting lipid metabolism. J. Clin. Lipidol.1(5), 466 (2007).
   Google Scholar
• Malik S, Wong ND, Franklin S, Pio J, Fairchild C, Chen R. Cardiovascular disease in US patients with metabolic syndrome, diabetes, and elevated C-reactive protein. Diabetes Care28(3), 690–693 (2005).
   PubMed Web of Science ®Google Scholar
• Ray KK, Cannon CP, Cairns R et al. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 Trial. J. Am. Coll Cardiol.46(8), 1417–1424 (2005).
   PubMed Web of Science ®Google Scholar
• Kinlay S. Low-density lipoprotein-dependent and -independent effects of cholesterol-lowering therapies on C-reactive protein – a meta-analysis. J. Am. Coll. Cardiol.49(20), 2003–2009 (2007).
   PubMed Web of Science ®Google Scholar
• Arnaud C, Burger F, Steffens S et al. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes – new evidence for direct antiinflammatory effects of statins. Arterioscler. Thromb. Vasc. Bio.25(6), 1231–1236 (2005).
   PubMed Web of Science ®Google Scholar
• Seedorf U, Engel T, Lueken A, Bode G, Lorkowski S, Assmann G. Cholesterol absorption inhibitor Ezetimibe blocks uptake of oxidized LDL in human macrophages. Biochem.Biophys. Res. Comm.320(4), 1337–1341 (2004).
   PubMed Web of Science ®Google Scholar
• Orso E, Werner T, Wolf Z, Bandulik S, Kramer W, Schmitz G. Ezetimibe influences the expression of raft-associated antigens in human monocytes. Cytometry A69(3), 206–208 (2006).
   PubMedGoogle Scholar
• McNamara JR, Shah PK, Nakajima K et al. Remnant-like particle (RLP) cholesterol is an independent cardiovascular disease risk factor in women: results from the Framingham Heart Study. Atherosclerosis154(1), 229–236 (2001).
   PubMed Web of Science ®Google Scholar
• Karpe F, Boquist S, Tang R, Bond GM, de Faire U, Hamsten A. Remnant lipoproteins are related to intima-media thickness of the carotid artery independently of LDL cholesterol and plasma triglycerides. J. Lipid Res.42(1), 17–21 (2001).
   PubMed Web of Science ®Google Scholar
• Imke C, Rodriguez BL, Grove JS et al. Are remnant-like particles independent predictors of coronary heart disease incidence? The Honolulu Heart study. Arterioscler. Thromb. Vasc. Biol.25(8), 1718–1722 (2005).
   PubMed Web of Science ®Google Scholar
• Twicker TB, Dallinga-Thie GM, Cohn JS, Chapman MJ. Elevated remnant-like particle cholesterol concentration – a characteristic feature of the atherogenic lipoprotein phenotype. Circulation109(16), 1918–1925 (2004).
   PubMed Web of Science ®Google Scholar
• Cohn JS, Marcoux C, Davignon J. Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins. Arterioscler. Thromb. Vasc. Biol.19(10), 2474–2486 (1999).
   PubMed Web of Science ®Google Scholar
• Harchaoui KE,van der steeg WA, Stores ES. Value of Low-density lipoprotein particle number and size as predictor of coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective population study. J. Am. Coll. Cardiol.49, 547–553 (2007).
   PubMed Web of Science ®Google Scholar
• Packard CJ, Ford I, Robertson M et al. Plasma lipoproteins and apolipoproteins as predictors of cardiovascular risk and treatment benefit in the PROspective Study of Pravastatin in the Elderly at Risk (PROSPER). Circulation112(20), 3058–3065 (2005).
   PubMed Web of Science ®Google Scholar
• St Pierre AC, Cantin B, Dagenais GR et al. Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler. Thromb. Vasc. Biol.25(3), 553–559 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenson RS, Otvos JD, Freedman DS. Relations of lipoprotein subclass levels and low-density lipoprotein size to progression of coronary artery disease in the Pravastatin Limitation of Atherosclerosis in the Coronary Arteries (PLAC-I) trial. Am. J. Cardiol.90(2), 89–94 (2002).
   PubMed Web of Science ®Google Scholar
• Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation82(2), 495–506 (1990).
   PubMed Web of Science ®Google Scholar
• Farnier M, Freeman MW, Macdonell G et al. Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia. Eur. Heart J.26(9), 897–905 (2005).
   PubMed Web of Science ®Google Scholar
• Tribble D, Farnier M, Freeman MW et al. Effect of fenofibrate and ezetimibe on lipoprotein subclasses and LDL subclass pattern in patients with mixed hyperlipidemia. Circulation110(17, Suppl.), III143–III144 (2004).
   Google Scholar
• Ose L, Olegario KQ, Reyes R, Johnson-Levonas AO, Sapre A, Tribble D. Effects of ezetimibe/simvastatin on lipoprotein subclasses in patients with primary hypercholesterolemia: an exploratory analysis of archived samples using two commercially available techniques. Clin. Ther.29(11), 2419–2432 (2007).
   PubMed Web of Science ®Google Scholar
• Kalogirou M, Tsimihodimos V, Gazi I et al. Effect of ezetimibe monotherapy on the concentration of lipoprotein subfractions in patients with primary dyslipidaemia. Curr. Med. Res. Opin.23(5), 1169–1176 (2007).
   PubMed Web of Science ®Google Scholar
• Kolovou GD, Anagnostopoulou KK, Salpea KD, Daskalopoulou SS, Mikhailidis DP. The effect of statins on postprandial lipemia. Curr. Drug Targets8(4), 551–560 (2007).
   PubMed Web of Science ®Google Scholar
• Chan YM, Varady KA, Lin Y et al. Plasma concentrations of plant sterols: physiology and relationship with coronary heart disease. Nutr. Rev.64(9), 385–402 (2006).
   PubMed Web of Science ®Google Scholar
• Normen L, Shaw CA, Fink CS, Awad AB. Combination of phytosterols and omega-3 fatty acids: a potential strategy to promote cardiovascular health. Curr. Med. Chem. Cardiovasc. Hematol. Agents2(1), 1–12 (2004).
   PubMedGoogle Scholar
• Matthan N, Larocque JM, Pencina M et al. Increased cholesterol absorption and decreased cholesterol synthesis characterize Framingham Offspring Study participants with coronary heart disease. Circulation112(17 Suppl. S), U892–U893 (2005).
   Google Scholar
• Fassbender K, Lutjohann D, Dik MG et al. Moderately elevated plant sterol levels are associated with reduced cardiovascular risk-The LASA study. Atherosclerosis (doi:10.1016/j.atherosclerosis.2006.10. 032) (2006).
   PubMedGoogle Scholar
• Pinedo S, Vissers MN, von Bergmann K et al. Plasma levels of plant sterols and the risk of coronary artery disease: the prospective EPIC-Norfolk Population Study. J. Lipid Res.48(1), 139–144 (2007).
   PubMed Web of Science ®Google Scholar
• Thiery J, Ceglarek U, Fiedler G et al. Elevated campesterol serum levels – a significant predictor of incident myocardial infarction: Results of the population-based MONICA/KORA follow-up study 1994 to 2005. Circulation114(18 Suppl. S), 884 (2006).
   Google Scholar
• Wilund KR, Yu L, Xu F et al. No association between plasma levels of plant sterols and atherosclerosis in mice and men. Arterioscler. Thromb. Vasc. Biol.24(12), 2326–2332 (2004).
   PubMed Web of Science ®Google Scholar
• John S, Sorokin AV, Thompson PD. Phytosterols and vascular diseases. Curr. Opin. Lipidol.18(1), 35–45 (2007).
   PubMed Web of Science ®Google Scholar
• Sudhop T, Lutjohann D, Reber D et al. Inhibition of intestinal cholesterol absorption and endogenous cholesterol synthesis by ezetimibe/simvastatin in humans. J. Am. Coll. Cardiol45(3 Suppl A), 392A (2005).
   Web of Science ®Google Scholar
• Assmann G, Kannenberg F, Musliner T, Ramey D, Veltri ER. Effects of ezetimibe, simvastatin, atorvastatin, and ezetimibe-statin therapies on non-cholesterol sterols in patients with primary hypercholesterolemia. Curr. Med. Res. Opin.24(1), 249–259 (2008).
   PubMed Web of Science ®Google Scholar
• Schroepfer GJ Jr. Oxysterols: modulators of cholesterol metabolism and other processes. Physiol. Rev.80(1), 361–554 (2000).
   PubMed Web of Science ®Google Scholar
• Staprans I, Pan XM, Rapp JH, Grunfeld C, Feingold KR. Oxidized cholesterol in the diet accelerates the development of atherosclerosis in LDL receptor- and apolipoprotein E-deficient mice. Arterioscler. Thromb. Vasc. Biol.20(3), 708–714 (2000).
   PubMed Web of Science ®Google Scholar
• Staprans I, Pan XM, Rapp JH, Feingold KR. Oxidized cholesterol in the diet is a source of oxidized lipoproteins in human serum. J. Lipid Res.44(4), 705–715 (2003).
   PubMed Web of Science ®Google Scholar
• Staprans I, Pan XM, Rapp JH, Moser AH, Feingold KR. Ezetimibe inhibits the incorporation of dietary oxidized cholesterol into lipoproteins. J. Lipid Res.47(11), 2575–2580 (2006).
   PubMed Web of Science ®Google Scholar
• Kastelein JJ, Sager PT, de Groot E, Veltri E. Comparison of ezetimibe plus simvastatin versus simvastatin monotherapy on atherosclerosis progression in familial hypercholesterolemia. Design and rationale of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial. Am. Heart J.149(2), 234–239 (2005).
   PubMed Web of Science ®Google Scholar
• Rossebo A, Pedersen T, Allen C et al. Design and baseline characteristics of the Simvastatin and Ezetimibe in Aortic Stenosis (SEAS) study. Am. J. Cardiol.99(7), 970–973 (2007).
   PubMed Web of Science ®Google Scholar
• Baigent C, Landry M. Study of heart and renal protection. Kidney Int.63(S84), 207–210 (2003).
   Web of Science ®Google Scholar
• Cannon CP, Guigliano RP, Blazing MA et al for the IMPROVE-IT investigators. Design and Rationale of IMPROVE-IT (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial): Comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes in patients with acute coronary syndrome. Am. Heart J. (2007). [Epub ahead of print].
   Google Scholar